INDEPENDENT ECM RESEARCH - US & APAC
The IPO & Placement Research
you won’t get from the banks
Aequitas is an independent equity research firm delivering timely, institutional-quality IPO and Placement analysis to investors.
Fundamental, bottom-up research
Proprietary quantitative framework overlay
Consistent analysis; every deal, every stage
We cover US and APAC deals over US$100m (ex-Biotech) from pre-IPO through to listing
US IPOs
over US$100m
APAC IPOs
over US$100m
APAC Placements over US$100m
APAC Lock-up
expiries
Ex Bio-tech. APAC includes Hong Kong, China ADRs, India, ASEAN, South Korea, Japan, Australia, New Zealand, and Asia-linked cross-border listings (ie Taiwan GDRs)
We recommend ‘avoid’ on ~60% of all IPOs,
with 73% accuracy
1,058
IPOS COVERED SINCE 2015
73.2% accuracy · 40.5% participation rate
1,645
PLACEMENTS COVERED SINCE 2015
69.5% accuracy · 75.5% participation rate